ATLPD0000032
Product-level evidence profile for identity and molecular form, PK exposure, clinical context, safety context, label material, and reproducible data access.
Formulation context: Injection, powder
Product identity and molecular form, PK exposure evidence, safety context, clinical and label context, interpretation boundaries, and reproducibility exits available for this product.
What is this product, which peptide does it map to, and what is its structure?
What is the drug used for and how does it act?
Are there curated exposure / PK summaries or cited observations?
What safety, postmarketing, and immune-recognition signals surround the product?
What trial and product-label context is attached to this product?
How is the evidence scoped, traced, cited, and reopened?
What the product is, how its complete molecular form is defined, and which chemical or structural representations support that identity.
This product identity anchors product-level label, trial, postmarketing, and PK context. Route, form, and holder fields are shown when they are normalized from product or label references, not inferred from the product name.
These anchors support product-level lookup and context attachment. They are identity evidence, not ADMET endpoint measurements.
ATC classification © WHO Collaborating Centre for Drug Statistics Methodology; used unmodified for non-commercial research.
Product-level label, safety, trial, and PK context may be read beside the linked peptide identity. Endpoint truth still remains controlled by endpoint-specific evidence and compatibility rules.
The public link view emphasizes sequence, identity role, reference support, and interpretation boundary rather than non-public peptide identifiers.
Multiple linked identities can reflect reviewed source-sequence differences, variant entries, or precursor-like entries. Use the reference identity as the main product-context link.
| Identity match | Reference | Link review |
|---|---|---|
| Reference identity | Evidence context | Linked peptide identity |
The link supports product-context interpretation beside a peptide identity. It is not a measured endpoint, and it does not promote label, safety, or trial context into peptide-level endpoint truth by itself.
Structure depiction isn't available for this peptide in the current release. The linked peptide record carries the reviewed sequence and any predicted model.
N-acetyl-D-2Nal-D-4Cpa-D-3Pal-L-Ser-L-4Aph(Hor)-D-4Aph(Cbm)-L-Leu-L-Lys(iPr)-L-Pro-D-Ala-NH2;acetatesalt
What the drug is used for and how it acts, based on curated therapeutic indications and mechanism-of-action evidence for the product identity.
Traceable exposure and PK properties across product labels, literature, and nonclinical evidence.
Human product-label values are shown first, followed by additional source-backed evidence.
Human exposure properties reported in official product labeling.
Other source-backed PK properties across labels, literature, and nonclinical studies.
Direct source values extend the product's PK endpoint profile.
| PK property | Value | Context | Reference | Measured material | Evidence role | Reported statement |
|---|---|---|---|---|---|---|
| AUC | 1,054 ng*d/mL | human · 240 mg at 40 mg/mL product concentration | Reference | Reported analyte | Source-reported product-label value | Following administration of FIRMAGON 240 mg at a product concentration of 40 mg/mL, the mean Cmax was 26.2 ng/mL (coefficient of variation, CV 83%) and the mean AUC was 1054 ng∙day/mL (CV 35%). |
| Bioavailability | ≈60 % | human · subcutaneous · plasma · FIRMAGON 20 mg/mL dose concentration | Reference | Reported analyte | Curated comparable measurement | The estimated values for bioavailability from population pharmacokinetic modelling were approximately 60% and 40% for dose concentrations 20 mg/mL and 40 mg/mL respectively. |
| Bioavailability | ≈40 % | human · subcutaneous · plasma · FIRMAGON 40 mg/mL dose concentration | Reference | Reported analyte | Curated comparable measurement | The estimated values for bioavailability from population pharmacokinetic modelling were approximately 60% and 40% for dose concentrations 20 mg/mL and 40 mg/mL respectively. |
| Clearance | ≈9 L/h | human · subcutaneous | Reference | Reported analyte | Source-reported product-label value | Following subcutaneous administration of degarelix to prostate cancer patients the clearance is approximately 9 L/hr. |
| Cmax | 26.2 ng/mL | human | Reference | Reported analyte | Source-reported product-label value | Following administration of FIRMAGON 240 mg at a product concentration of 40 mg/mL, the mean Cmax was 26.2 ng/mL (coefficient of variation, CV 83%) and the mean AUC was 1054 ng∙day/mL (CV 35%). |
| PPB | 90 % | human · plasma | Reference | Reported analyte | Source-reported product-label value | In vitro plasma protein binding of degarelix is estimated to be approximately 90%. |
| Tmax | <=172,800 seconds | human · subcutaneous | Reference | Reported analyte | Source-reported observation | Typically Cmax occurred within 2 days after subcutaneous administration. |
| Vd | >1 L/kg | human · intravenous | Reference | Reported analyte | Source-reported observation | Distribution The distribution volume of degarelix after intravenous (> 1 L/kg) or subcutaneous administration (> 1000L) indicates that degarelix is distributed throughout total body water. |
| Vd | >1,000 L | human · subcutaneous | Reference | Reported analyte | Source-reported observation | Distribution The distribution volume of degarelix after intravenous (> 1 L/kg) or subcutaneous administration (> 1000L) indicates that degarelix is distributed throughout total body water. |
Summaries keep species, unit, route, dose, matrix, population, and source context separate. Each value retains its cited measurement trace.
Regulatory safety warnings, postmarketing and nonclinical safety context, and immune-recognition context. These describe available signals, not incidence rates or causality.
Clinical-trial context and structured product-label references attached by product identity.
How to read, trace, cite, and reopen this profile: evidence scope, reference lineage, and reproducible data access.
Endpoint summaries, product-context lanes, identity links, and source references answer different questions. This boundary keeps the page useful without converting context into stronger claims than the current review layer supports.
Compare PK results only when endpoint and experimental context are compatible.
Label, trial, safety, immune, and nonclinical records remain contextual unless separately extracted as an endpoint.
Defined molecular entity
Comparable measurement layer
Endpoint-level interpretation when context fields match.
Pooled product parameters across mismatched species, units, route, dose, matrix, population, or source context.
Clinical, label, safety, immune, and nonclinical context
Reading the product's evidence surroundings and source-backed context lanes.
Incidence rates, causality claims, product safety ranking, or normalized ADMET endpoint values.
Molecular identity context
Reading product context beside a reviewed peptide identity.
Automatic transfer of every product-level signal to peptide-level endpoint evidence.
Reproducibility and source trace
Checking where labels, trials, safety reports, identity links, and curated measurements came from.
A substitute for normalized evidence, context grouping, or endpoint review.
Original-source reading path
Reading the source reference in its native regulatory, registry, literature, or source context.
Bypassing ADMETatlas curation status, interpretation boundaries, or endpoint-promotion policy.
Label, trial, safety, immune, identity-link, and PK evidence enter the product profile through different review paths. This module keeps their roles visible so users can trace evidence without over-reading context counts.
active reference families
source-matching traces
PK plus context entries
current product profile
Regulatory product-label context
Label sections, label-derived PK statements, safety wording, route, formulation, and immunogenicity context when extracted.
Label material supports product context. It becomes endpoint evidence only through the reviewed PK or endpoint extraction path.
Human study-registration context
Trial identity, phase/status, intervention matching, and availability of results context around the product.
Trial registry entries are study context unless endpoint-compatible results are extracted and reviewed separately.
Safety surveillance context
Signal-aware reading of reported adverse-event context around marketed products.
Report counts do not establish causality, incidence, or comparative product safety.
Assay and nonclinical support context
Immune-recognition assays, nonclinical safety context, and neighboring signals that help interpret the product profile.
These entries are not clinical incidence or endpoint truth unless a review policy promotes a specific endpoint.
Named-product identity support
Matching named and dosed product presentations to a stable medication identity.
Identity records do not provide an endpoint value, administration outcome, or route-specific clinical result.
Source-matching and identity-review context
Source records used to assess product-to-peptide identity relationships and retained audit context.
Only an exact match to the current authoritative canonical identity supports a linked identity; all other traces remain product context.
Endpoint measurement trace
Rechecking source values, units, route, dose, matrix, population, and source context for PK summaries.
PK entries remain context-bound measurements and should not be pooled across incompatible contexts.
Link references and selected label entries carry direct source links. Product-context entries may instead carry source labels and curated summaries in the structured profile. Both are provenance, but only direct reference fields should be displayed as citation links.
The structured profile access reopens the same product view used by this page, including molecular identity, PK evidence, product context, and reference lineage for the current public release.
public product profile
identity link scope
cited measurement trace
40 context · 2 identity support
label plus link traces
Use the product profile access for product-specific reproducibility. Use full-release downloads for catalog-scale analysis, with the current source policy and data dictionary.
Current product
Machine-readable profile for molecular identity, PK evidence summaries, product context, and reference lineage.
Uses the public ATL product ID in the URL. Non-public product identifiers remain outside the navigation label.
The request returns the structured product profile used by this page. It is the current product-specific reproducibility path while product-only tabular exports remain a release follow-up.
curl -sS 'https://admetatlas.scbdd.com/api/v1/products/ATLPD0000032' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Use this module to reproduce the current product profile and locate full-release exports. Cross-product comparison still depends on compatible endpoint, species, route, dose, matrix, population, source, identity-link, and review context.